Karyopharm Therapeutics (KPTI) Accumulated Expenses (2012 - 2026)

Karyopharm Therapeutics (KPTI) has 14 years of Accumulated Expenses data on file, last reported at $4.4 million in Q4 2025.

• Quarterly Accumulated Expenses fell 68.53% year-over-year to $4.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $4.4 million (down 68.53% YoY) and the FY2025 annual result came in at $4.4 million, down 68.53% from the prior year.
• Accumulated Expenses retreated to $4.4 million in Q4 2025, from $66.3 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $66.3 million in Q3 2025 to a low of $4.4 million in Q4 2025.
• A 5-year average of $45.3 million and a median of $54.0 million in 2021 frame the typical range for Accumulated Expenses.
• Annual changes were most pronounced in 2021 — Accumulated Expenses surged 38.86% — and 2025, when it sank 68.53%.
• Tracing KPTI's Accumulated Expenses over 5 years: stood at $22.0 million in 2021, then tumbled by 46.89% to $11.7 million in 2022, then increased by 15.26% to $13.5 million in 2023, then advanced by 3.43% to $13.9 million in 2024, then tumbled by 68.53% to $4.4 million in 2025.
• The last three Accumulated Expenses figures came in at $4.4 million (Q4 2025), $66.3 million (Q3 2025), and $62.9 million (Q2 2025), per Business Quant data.